Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial).
Robert Dreicer
Consultant or Advisory Role - AbbVie; Dendreon; Endo Pharmaceuticals; Janssen; Millennium
Research Funding - Endo Pharmaceuticals; Millennium; Progenics
Robert Jones
Honoraria - Astellas Pharma; Janssen; Sanofi
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Medivation; Millennium; Sanofi
Stephane Oudard
Consultant or Advisory Role - Astellas Pharma; Janssen; Keocyt; Sanofi ; Takeda
Honoraria - Janssen; Sanofi ; Takeda
Eleni Efstathiou
Consultant or Advisory Role - Bayer; Janssen; Medivation; Millennium; Sanofi
Honoraria - Janssen; Millennium; Sanofi ; Takeda
Research Funding - Janssen; Millennium; Sanofi ; Takeda
Fred Saad
Consultant or Advisory Role - Astellas Pharma; Janssen; Millennium; Sanofi
Research Funding - Astellas Pharma; Janssen; Millennium; Sanofi
Ronald De Wit
Consultant or Advisory Role - Millennium
Honoraria - Millennium
Research Funding - Millennium
Johann Sebastian De Bono
No relevant relationships to disclose
Yuanjun Shi
Employment or Leadership Position - Takeda
Bindu Tejura
Employment or Leadership Position - Takeda
Stock Ownership - Millennium
David B. Agus
Consultant or Advisory Role - Millennium
Niels Geert Borgstein
Employment or Leadership Position - Takeda
Stock Ownership - Takeda
Joaquim Bellmunt
Consultant or Advisory Role - Millennium
Karim Fizazi
Consultant or Advisory Role - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Dendreon; Ipsen; Janssen; Millennium; Novartis; Sanofi